A similar association (p = 0.004) between KRAS mutations and resistance was observed in colorectal cancer (CRC) cell lines, where KRAS mutations are frequent (mutations in 13/22 lines; 59%) (Fig. 1d), indicating that the association with resistance is not driven by the general responsiveness of individual tumor types. This evidence concerns the gene KRAS and neoplasm.